These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1672572)

  • 1. Evaluation of direct pharmacist intervention on conversion from parenteral to oral histamine H2-receptor antagonist therapy.
    Kirking DM; Svinte MK; Berardi RR; Cornish LA; Chaffee BW; Ryan ML
    DICP; 1991 Jan; 25(1):80-4. PubMed ID: 1672572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment: parenteral H2-receptor antagonist intervention.
    Glazier HS
    DICP; 1991 Jun; 25(6):681-2. PubMed ID: 1678906
    [No Abstract]   [Full Text] [Related]  

  • 3. Physician opinion of pharmacist-initiated change from injectable to oral administration of histamine H2-receptor antagonists.
    Kirking DM; Bickley SK; Wasserman ML
    Am J Hosp Pharm; 1991 Aug; 48(8):1722-7. PubMed ID: 1680293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous histamine H2-receptor antagonists and parenteral nutrition: patterns of use.
    Bone BM; Maksym CJ; Kirking DM; Georgal BA; Jarvis CL; Dunn-Kucharski VA; Berardi RR
    Am J Health Syst Pharm; 1995 May; 52(10):1082-6. PubMed ID: 7656098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy.
    Caldwell RD; Davis SK
    Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in prescribing patterns of intravenous histamine2-receptor antagonists results in significant cost savings without adversely affecting patient care.
    Fudge KA; Moore KA; Schneider DN; Sherrin TP; Wellman GS
    Ann Pharmacother; 1993 Feb; 27(2):232-7. PubMed ID: 8094986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of histamine (H2)-receptor antagonists in total parenteral nutrition patients.
    Baptista RJ
    Am J Med; 1987 Dec; 83(6A):53-7. PubMed ID: 2892408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IV additive program saves Montreal hospital $300,000.
    Torchinsky A
    Health Care (Don Mills); 1986 Jun; 28(5):25-8. PubMed ID: 10277322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
    Kane MP; Briceland LL; Garris RE; Favreau BN
    Am J Hosp Pharm; 1990 Sep; 47(9):2007-10. PubMed ID: 1977317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for selection of parenteral histamine (H2)-receptor antagonists.
    Wolfe MM
    Am J Med; 1987 Dec; 83(6A):82-8. PubMed ID: 2892411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new histamine H2-receptor antagonist ranitidine. Duration of action.
    Dammann HG; Simon B
    Scand J Gastroenterol Suppl; 1981 Jun; 69():39-43. PubMed ID: 6119781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pharmacists' clinical interventions on nonformulary drug use.
    Packer LA; Mahoney CD; Rich DS; Jeffrey LP
    Am J Hosp Pharm; 1986 Jun; 43(6):1461-6. PubMed ID: 3728481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacist-initiated program of intravenous to oral antibiotic conversion.
    Przybylski KG; Rybak MJ; Martin PR; Weingarten CM; Zaran FK; Stevenson JG; Levine DP
    Pharmacotherapy; 1997; 17(2):271-6. PubMed ID: 9085318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of histamine2-receptor blocking agents and sucralfate in a health maintenance organization following continued clinical pharmacist intervention.
    Mead RA; McGhan WF
    Drug Intell Clin Pharm; 1988 Jun; 22(6):466-9. PubMed ID: 2899491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
    Chase SL; Peterson AM; Wordell CJ
    Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
    Mainie I; Tutuian R; Castell DO
    J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Productivity and quality assessment associated with conversion from i.v. to oral ranitidine.
    Baciewicz AM; Cowan RI
    Hosp Formul; 1993 Apr; 28(4):397-8. PubMed ID: 10125324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.